Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status (vol 138, pg 1516, 2016)

被引：0
|
作者：
Kato, J.
Futamura, M.
Kanematsu, M.
Gaowa, S.
Mori, R.
Tanahashi, T.
Matsuhashi, N.
Yoshida, K.
机构：
来源：
INTERNATIONAL JOURNAL OF CANCER | 2016年 / 139卷 / 01期
关键词：
D O I：
10.1002/ijc.30045
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E2
页数：2
相关论文
共 18 条
  • [1] Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
    Kato, Junko
    Futamura, Manabu
    Kanematsu, Masako
    Gaowa, Siqin
    Mori, Ryutaro
    Tanahashi, Toshiyuki
    Matsuhashi, Nobuhisa
    Yoshida, Kazuhiro
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (06) : 1516 - 1527
  • [2] Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line
    Kamran, Shiva
    Seyedrezazadeh, Ensiyeh
    Shanehbandi, Dariush
    Asadi, Milad
    Zafari, Venus
    Shekari, Najibeh
    Namvar, Leila
    Zarredar, Habib
    JOURNAL OF GASTROINTESTINAL CANCER, 2022, 53 (03) : 597 - 604
  • [3] Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line
    Shiva Kamran
    Ensiyeh Seyedrezazadeh
    Dariush Shanehbandi
    Milad Asadi
    Venus Zafari
    Najibeh Shekari
    Leila Namvar
    Habib Zarredar
    Journal of Gastrointestinal Cancer, 2022, 53 : 597 - 604
  • [4] Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations
    Jia, Yi-Tao
    Yang, Dong-Hai
    Zhao, Zhaolong
    Bi, Xiao-Hui
    Han, Wei-Hua
    Feng, Bo
    Zhi, Jie
    Gu, Bin
    Duan, Zhihui
    Wu, Jian-Hua
    Ju, Ying-Chao
    Wang, Ming-Xia
    Li, Zhong-Xin
    CURRENT CANCER DRUG TARGETS, 2018, 18 (03) : 278 - 286
  • [5] Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro (vol 36, pg 1085, 2015)
    Qiao, Han
    Wang, Ting-yu
    Yan, Wei
    Qin, An
    Fan, Qi-ming
    Han, Xiu-guo
    Wang, Yu-gang
    Tang, Ting-ting
    ACTA PHARMACOLOGICA SINICA, 2019, 40 (08) : 1127 - 1128
  • [6] Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis (vol 380, pg 87, 2016)
    Lu, Yun-Xin
    Ju, Huai Qiang
    Wang, Feng
    Chen, Le-Zong
    Wu, Qi-Nian
    Sheng, Hui
    Mo, Hai-Yu
    Pan, Zhi-Zhong
    Xie, Dan
    Kang, Tie Bang
    Chen, Gong
    Yun, Jing-Ping
    Zeng, Zhao-Lei
    Xu, Rui Hua
    CANCER LETTERS, 2020, 469 : 526 - 526
  • [7] L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells (vol 95, pg 200, 2016)
    Jung, S. A.
    Lee, D. H.
    Moon, J. H.
    Hong, S. W.
    Shin, J. S.
    Hwang, I. Y.
    Shin, Y. J.
    Kim, J. H.
    Gong, E. Y.
    Kim, S. M.
    Lee, E. Y.
    Lee, S.
    Kim, J. E.
    Kim, K. P.
    Hong, Y. S.
    Lee, J. S.
    Jin, D. H.
    Kim, T.
    Lee, W. J.
    FREE RADICAL BIOLOGY AND MEDICINE, 2016, 97 : 620 - 620
  • [8] RETRACTION: miR-448 suppresses proliferation and invasion by regulating IGF1R in colorectal cancer cells (Retraction of Vol 8, Pg 3013, 2016)
    Li, B.
    Ge, L.
    Li, M. H.
    Wang, L.
    Li, Z. H.
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (01): : 675 - 675
  • [9] RETRACTED: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells (Retracted article. See vol. 138, pg. 2050, 2016)
    Narayanan, Narayanan K.
    Narayanan, Bhagavathi A.
    Bosland, Maarten
    Condon, Mark S.
    Nargi, Dominick
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (07) : 1586 - 1598
  • [10] Retraction Statement: Inhibition of protein phosphatase 5 (PP5) suppresses survival and growth of colorectal cancer cells (vol 62, pg 621, 2015)
    Wang, J.
    Zhu, J.
    Dong, M.
    Yu, H.
    Dai, X.
    Li, K.
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2024, 71 (03) : 691 - 691
12